Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.

Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...

Drug-coated balloon (DCB) angioplasty has become a valuable alternative to drug-eluting stents in treating coronary artery disease. To achieve optimal outcomes, proper lesion preparation and techniques to minimise drug loss are crucial.

This article highlights key steps and best practices for performing DCB angioplasty, ensuring effective drug delivery and...

Mitral transcatheter edge-to-edge repair (M-TEER) has reshaped the prognosis for heart failure patients with secondary mitral regurgitation, but recurrence remains a real challenge when surgical options are off the table.

This case highlights an innovative use of an atrial flow regulator (AFR) to manage elevated left atrial...

Impella CP microaxial flow pump supports complete revascularisation during high-risk PCI, but standard implantation often leads to vascular complications. This article explores an initial experience with a sheathless implantation technique, which shows promise as a feasible and safe alternative.

Aaysha Cader provides her take on the DCB-BIF Trial presented by Shao-Liang Chen at TCT 2024 in Washington.

Paris, France, 14-17 May 2024. The Course Directors have selected 3 major Late Breaking Trials (LBTs) that were presented for the first time during the 2024 edition of EuroPCR. These trials were selected on account of their design, outcomes and potential to influence daily clinical practice....

Explore the global challenge of hypertension, affecting one in three adults, and the strategies for screening, diagnosis, and management, including lifestyle modifications, pharmacotherapy, and device-based treatments, as outlined by Sofie Brouwers.

Paris, France, 20-23 May 2025. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during the 2025 edition of EuroPCR. These trials were selected because of their design, results, and potential to impact practice, among which is the...

Authored by Hector Garcia-Garcia and Jorge Sanz-Sanchez, this article examines pivotal randomized clinical trials on drug-coated balloons in coronary artery disease. It highlights their role in managing in-stent restenosis, de novo small vessel lesions, and large vessel lesions while exploring future directions through ongoing trials.

Paris, France. 21 May 2021.  Since 1989, EuroPCR has constantly pioneered innovative educational tools and formats to help the interventional cardiovascular community effectively share their knowledge, skills and practice. Rising up to the challenge of the pandemic, the 31st annual edition was fundamentally rethought, reshaped and...

Nicola Ryan provides her take on this clinical trial presented by Lisa Mielniczuk at the American College of Cardiology Scientific Session (ACC.23/WCC) – note this analysis is based upon the presented slides alone.

Luigi Biasco provides his take on the clinical trial presented by John K. Forrest from Yale University School of Medicine, New Haven, Connecticut, USA during the 2023 ACC/WCC annual congress held in New Orleans, Louisiana.

REDUCE-AMI is a multicentre, registry-based, prospective open-label parallel-group randomised clinical trial evaluating the benefit of beta-blocker treatment in patients with acute MI and an ejection fraction >50% treated with a contemporary reperfusion strategy.

Nicola Ryan and Ali Nazmi Calik provide their take on the results which were presented...

Alex Sticchi provides his take on the 5-year outcomes from PARTNER 3 Low Risk which were presented by Martin B. Leon at TCT Congress 2023.

Nicola Ryan reports on the BIOFLOW DAPT trial results presented during the ESC 2023 Congress in Amsterdam by Marco Valgimigli and published in Circulation.

BIOFLOW-DAPT is an open-label randomised trial comparing the safety and efficacy of a biodegradable-polymer sirolimus-eluting stent with a durable-polymer zotarolimus-eluting stent in high-bleeding risk patients...